What Does an Advanced Insulin Pump Cost—and Is It Worth It? New Australian Research Offers Insight

For adults with Type 1 diabetes whose blood sugar levels remain above target despite treatment, there are several paths forward. Some people use multiple daily injections of insulin along with continuous glucose monitoring (CGM). Others use an automated hybrid closed-loop system like the MiniMed 780G—an insulin pump that adjusts doses automatically based on CGM readings.

Both approaches work, but they differ in convenience, precision, and cost. A new economic analysis from Australia looked at which approach delivers better long-term value. The researchers asked: Does the improved blood sugar control from an automated pump justify its higher expense?

The study was based on data from a randomized controlled trial that compared the two approaches in people starting with an average HbA1c of 9.04%—above the typical target of 7% or lower.

People using the MiniMed 780G lowered their HbA1c by 1.54 percentage points. Those using multiple daily injections plus CGM lowered theirs by 0.2 percentage points. The pump-based approach produced notably better glycemic control, which over time can help reduce the risk of diabetes complications.

The researchers projected costs and health outcomes over 50 years, accounting for the price of equipment, supplies, healthcare visits, and the value of avoided complications. They found that the MiniMed 780G was more expensive overall—about AUD $49,522 more across 50 years. However, it was also associated with approximately 1.5 additional quality-adjusted life years (QALYs)—a measure that combines both how long someone lives and how well they feel during those years.

When researchers divided the extra cost by the extra health benefit, they calculated a cost per QALY of AUD $32,840. In health economics, this is generally considered reasonable value—though what constitutes 'good value' varies by country and healthcare system.

One striking finding: the financial case for the pump weakens significantly over shorter periods. When the researchers looked at just 20 years instead of 50, the cost per QALY jumped above AUD $50,000. This makes sense: the pump's higher upfront cost takes time to recover through prevented complications and improved quality of life.

The analysis was also sensitive to factors like how often low blood sugar events occur and their impact on daily life. These factors can shift the balance of whether the pump is worth the investment for any individual person.

This research helps policymakers and healthcare systems think about which tools deserve funding. But individual decisions are more personal. The 'right' choice depends on factors this analysis doesn't fully capture: your specific blood sugar patterns, how much time you want to spend managing diabetes, your access to supplies, and your preferences.

If you're considering an automated pump, these findings suggest that over many years, the improved blood sugar control and quality-of-life benefits may outweigh the higher costs. A conversation with your diabetes care team can help you explore whether it's the right option for your situation.

Source: Advances in therapy. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.